This research fund supports Mayo researchers in infectious diseases who are making significant progress to address the newly emerging pathogens for COVID-19 and related viruses. As one example, Mayo experts are developing a vaccine using existing vaccine platforms, as well as gene therapy, that have been successfully applied against influenza, HIV, Ebola, Zika and Clostridium difficile. Research in emerging pathogens also lays the foundation for standard operating processes to address future pandemics.
Benefactor gifts will support Mayo Clinic’s COVID-19 testing capacity as well as expedite processing and response time. Gifts will support plans to offer COVID-19 testing beyond Mayo Clinic in an effort to help patients everywhere get the best care possible.
Mayo Clinic, Amazon, others launch collaboration to increase COVID-19 testing, vaccine development